Distant metastasis to liver, lung, brain, or bone occurs by circulating tumor cells (CTC). We hypothesized that a subset of CTC had features that are more malignant than tumor cells at the primary site. We established a highly malignant cell line, Panc-1-CTC, derived from the human pancreatic cancer cell line Panc-1 using an in vivo selection method. Panc-1-CTC cells showed greater migratory and invasive abilities than its parent cell line in vitro. In addition, Panc-1-CTC cells had a higher tumor-forming ability than parent cells in vivo. To examine whether a difference in malignant phenotypes exists between Panc-1-CTC cells and parent cells, we carried out comprehensive gene expression array analysis. As a result, Panc-1-CTC significantly expressed transforming growth factor beta-induced (TGFBI), an extracellular matrix protein, more abundantly than did parent cells. TGFBI is considered to regulate cell adhesion, but its functions remain unclear. In the present study, knockdown of TGFBI reduced cell migration and invasion abilities, whereas overexpression of TGFBI increased both abilities. Moreover, elevated expression of TGFBI was associated with poor prognosis in patients with pancreatic cancer. The number of CTC is associated with poor prognosis in breast, colorectal, prostate, and pancreatic cancer. 7-12 However, capturing living CTC from cancer patients and analyzing their biological features is difficult as a result of technical limitations. 13 Although the establishment of a CTC cell line from patients with cancer has been Abbreviations: CTC, circulating tumor cell; PDAC, pancreatic ductal adenocarcinoma;
| INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of cancer-related mortality in developed countries and has an extremely poor prognosis even if curative surgery is conducted. 1 Most patients with pancreatic cancer die of distant metastasis, most commonly liver metastasis. 2 However, metastasis is not a straightforward event for each tumor cell because of the complex processes required. The first step for distant metastasis is cell growth at the primary site. After that, these tumor cells promote invasion into the ECM and intravasate into the blood vessel or lymph duct. Then, CTC, the tumor cells that intravasate into the blood vessel, must survive the stressful environment of the bloodstream. Most CTC are killed by anoikis, a type of apoptosis, in the bloodstream before achieving metastasis. 3 CTC that evade anoikis can arrive at distant organs, leading to metastasis. CTC also form clusters of various sizes (CTC clusters) and contribute to metastasis by causing embolization in capillary vessels. [4] [5] [6] The number of CTC is associated with poor prognosis in breast, colorectal, prostate, and pancreatic cancer. [7] [8] [9] [10] [11] [12] However, capturing living CTC from cancer patients and analyzing their biological features is difficult as a result of technical limitations. 13 Although the establishment of a CTC cell line from patients with cancer has been reported in colon cancer, 14 the biological analysis of living CTC from PDAC has only been reported in a mouse research model. 15 Transforming growth factor beta-induced protein (TGFBI), also known as βIG-H3, kerato-epithelin, and RGD-CAP, is a secretory ECM protein. TGFBI binds to various types of collagen, such as fibronectin, laminin, and secreted protein acidic and cysteine rich (SPARC). TGFBI has several motifs for cell adhesion within the fasciclin-like (FAS1) domain, an extracellular domain comprising approximately 140 amino acid residues. 16, 17 The role of TGFBI in cancer has two aspects as a cell adhesive protein [18] [19] [20] and as an anti-cell adhesive protein. 21, 22 In addition, DNA hypermethylation of TGFBI has been observed in several tumor types, and TGFBI is thought to be a tumor suppressor protein for lung and ovarian cancer. 23, 24 In contrast, TGFBI is considered an oncogene for colon cancer, esophagus squamous carcinoma, melanoma and renal cancer. [25] [26] [27] [28] [29] Mechanisms underlying its bimodality have not been fully understood so far. 24 Additionally, the role of TGFBI has not been clarified in PDAC.
In the present study, we hypothesized that CTC had greater malignant potential than tumor cells at the primary site and that analyzing their biological features would be useful for elucidating metastasis. Therefore, we tried to capture CTC using a mouse xenograft model with the PDAC cell line Panc-1, and we then 
| MATERIALS AND METHODS

| Cell culture, primary tissue samples from patients with PDAC, and immunohistochemical analysis
Human pancreatic cancer cell lines Panc-1, CFPAC-1, and CAPAN-1 were purchased from ATCC (Manassas, VA, USA). All cells were grown in DMEM supplemented with 10% FBS in a humidified atmosphere with 5% CO 2 at 37°C. In the present study, Panc-1 was authenticated by short tandem repeat analysis. Other cell lines were authenticated through monitoring of cell morphology. TGF-β was purchased from R&D Systems (Minneapolis, MN, USA). SD-208
(TGF-β type I receptor inhibitor) was purchased from Fujifilm (Tokyo, Japan 
| Cell growth, migration and invasion assays
Number of viable cells at various time points after transfection was assessed by a colorimetric water-soluble tetrazolium salt (WST-8)
assay as described elsewhere. 30 Transwell migration and invasion assays were carried out in 24-well modified chambers without (migration) or with (invasion) Matrigel precoating (BD BioCoat; BD Biosciences), as described elsewhere. Gene expression values were evaluated as ratios based on the differences in cycle threshold values between the genes of interest and an internal reference gene (GAPDH), which served as a normalization factor for the amount of RNA isolated from the s.c. tumors.
Primer forward sequence (GAPDH), CGACCACTTTGTCAAGCT CA; primer reverse sequence (GAPDH), AGGGGTCTACATGGC AACTG.
| Plasmid construction
Full-length human TGFBI cDNA was obtained by PCR of Panc-1-P cDNA.
Primer forward sequence (TGFBI), TTAAGCTTATGGCGCTCTTCG TGCGGCT; primer reverse sequence (TGFBI), TTCTCGAGATGCTTCA TCCTCTCTAATA.
The plasmid for TGFBI expression (pCMV-3Tag3A-TGFBI) was obtained by cloning the full coding sequences into the vector pCMV-3Tag3A (Agilent Technologies, Santa Clara, CA, USA). (Thermo Fisher Scientific) were purchased from the indicated companies. Western blotting analyses were carried out as described elsewhere. 30 
| Western blot analysis
| Preparation of conditioned medium
Cells were seeded on a 75 cm 3 flask and cultured with growth medium until they reached the target confluence. The cells were washed with PBS and incubated in 15 mL DMEM without FBS for 24 hours.
The conditioned medium was centrifuged at 6000 × g for 10 minutes using Amicon Ultra filters (Merck Millipore, Billerica, MA, USA).
| Gene expression array analysis and gene set enrichment analysis
Analysis of gene expression profiles was carried out using SurePrint G3 Gene Expression Microarrays Ver. 3 (Agilent Technologies) according to the manufacturer's instructions. The raw data were analyzed with GeneSpring GX14.9 software (Agilent Technologies).
Gene set enrichment analysis (GSEA) was carried out with expression array data normalized by GeneSpring GX14.9. 
|
| Cell adhesion assay
| Statistical analysis
| Data deposition
The microarray data from this publication have been submitted to the GEO database (http://www.ncbi.nlm.nih.gov/geo/) and assigned the identifier "GSE118556". (Table S1 ). Figure 2C Table S2 ).
There was no correlation between TGFBI expression and Smad4 
| Effect of TGFBI on Panc-1 parent cell migration and invasion
Panc-1-P cells were transfected with empty vector (Negative control)
or TGFBI vector for the evaluation of the effect of TGFBI overexpression. First, we established a cell line that stably expresses TGFBI in Panc-1-P cells. mRNA and protein expression levels of TGFBI were confirmed by qRT-PCR and western blotting ( Figure 5A ,B), and in vitro cell growth in these transduced cell lines was almost the same ( Figure 5C ). In addition, we observed that TGFBI was secreted into the culture medium ( Figure 5B ). In contrast, TGFBI-overexpressing Panc-1-P cells enhanced anchorage-independent cell growth and increased migration and invasion abilities compared to cells transfected with empty vector ( Figure 5D ,E,F). These findings indicated that TGFBI might regulate stem cell features, cell migration and invasion, but not cell growth. Then, we carried out GSEA with expression array data. As a result, GSEA showed upregulation of stemness-related genes (GO term: GO_SOMATIC_STEM_CELL_POPULA-TION_MAINTENANCE) in Panc-1-CTC cells ( Figure S3 ).
| Expression of TGFBI was associated with poor prognosis in patients with PDAC
To determine the clinicopathological significance of TGFBI upregulation in patients with PDAC, we conducted an immunohistochemical analysis with anti-TGFBI antibody in 75 PDAC cases. Expression of TGFBI was mainly located in the ECM, and strong immunoreactivity for TGFBI was found in 19 cases, which coincided with the staining pattern of Panc-1-CTC s.c. tumors, whereas weak or no immunoreactivity for TGFBI was found in 56 cases ( Figure 6A ). TGFBI protein expression in each tumor was not associated with any clinicopathological characteristics (Table S3 ). In Kaplan-Meier survival curves, univariate analyses of overall and disease-free survival with log-rank tests showed a significant association between strong TGFBI immunoreactivity and poor patient survival (P < 0.0001 and P = 0.0014, respectively) ( Figure 6B,C) . In the Cox proportional hazard regression model, univariate analyses showed that TGFBI immunoreactivity, UICC stage, and adjuvant chemotherapy were significantly associated with overall survival (Table S4) . Moreover, multivariate analysis using a stepwise Cox regression procedure showed that TGFBI immunoreactivity was an independent predictive factor for overall survival. These results suggested that TGFBI could be a novel biomarker for predicting the prognosis of patients with PDAC.
| DISCUSSION
Most CTC are killed by anoikis, a type of apoptosis, in the bloodstream before achieving metastasis; therefore, capturing and analyzing surviving CTC are challenging and meaningful for identifying the characteristics of CTC. There are few reports about the establishment of a human CTC cell line or comprehensive genomic analysis of CTC because of the technical difficulty in isolating CTC. 31 In the present study, we applied an in vivo selection method modified from a previously reported procedure as a preclinical approach for the establishment of CTC cells from Panc-1-P cells. 32 This CTC-capturing method was simple, did not require a special machine and was not restricted by tumor cell size or cell surface markers such as cytokeratin, CD45, and EpCAM. 32 Although the establishment of a CTC cell line was not an easy task, we finally obtained one cell line termed (Table S1) (Table S2 ).
However, there was no relationship between SMAD4 mutation status and TGFBI expression level ( Figure 3F and Table S2 ). These observations coincide with the previous research. | 3629
EMT and TGFBI, and TGFBI overexpression promoted invasiveness of head and neck squamous cell carcinoma cells, whereas TGFBI knockout decreased their invasiveness. 37 With respect to the cell adhesion property of the ECM, TGFBI has two aspects. In some studies, TGFBI can promote cell adhesion, 20, 21 but in other studies, TGFBI can inhibit cell adhesion to components of the ECM, such as collagen. 22, 23 In the present study, High expression of TGFBI in clinical PDAC tissues is observed in 50%-96% of patients. 38, 39 In addition, the expression of TGFBI is associated with poor prognosis in colorectal cancer. 27 Our clinical data showed that the expression of TGFBI was also associated with poor prognosis in patients with PDAC. In clinical PDAC samples, TGFBI mRNA expression was predominantly observed in the cytoplasm of pancreatic cancer cells by the in situ hybridization method. 36 Another study also indicated that s.c. tumors derived from a melanoma cell line with shRNA-mediated suppression of TGFBI had significantly lower . Differences were analyzed by t test. E,F, Number of migratory (E) and invasive cells (F) through the Boyden chamber at 24 h after replating was counted using Diff-Quick Stain. Data are presented as mean ± SD of samples (n = 3). Differences were analyzed by the Mann-Whitney U test F I G U R E 6 Expression of transforming growth factor beta-induced (TGFBI) was associated with poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). A, Representative images of immunohistochemical staining of TGFBI protein in PDAC tissues. Bars, 100 μm. B, C, Kaplan-Meier curves for the overall survival (B) and disease-free survival (C) of 75 patients with primary PDAC. High TGFBI immunoreactivity in tumor tissues was significantly associated with poor overall and disease-free survival (P < 0.001 and P = 0.014, respectively; log-rank test) expression of TGFBI in the ECM than that of its nonsuppressed counterpart. 21 In addition, various types of normal cells, such as fibroblast cells and keratinocytes, secrete TGFBI in response to TGF-β signaling. 40 A previous report suggested that the high expression of TGFBI in the cytoplasm of tumor cells and the ECM in colorectal cancer was mediated by an autocrine TGF-β signal from several human cells, including stromal fibroblasts and tumor cells. 27 These observations suggested that TGFBI in the ECM might be derived from tumor cells and several types of cells. In the present study, consistent with the immunoreactivity of TGFBI in Panc-1-CTC xenograft tissue, the localization of TGFBI in clinical PDAC tissues was mainly the ECM and cytoplasm in tumor cells. Taken together, our results indicated that the expression of TGFBI in Panc-1-CTC xenograft tissues was derived from the tumor cells, and TGFBI might accumulate in the ECM.
In conclusion, we identified TGFBI as an oncogene using the viable CTC capturing method and showed that TGFBI was associated with the migration and invasion abilities of pancreatic cancer cells. In PDAC clinical samples, TGFBI was relatively abundant in the tumor ECM, and its expression was associated with patient prognosis. Moreover, the expression of TGFBI in both the cytoplasm of tumor cells and the ECM could be a biomarker for the prediction of prognosis in PDAC.
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